The Wulff: Debunking the Big Bank-tank narrative
The Wulff is Stockhead’s regular wrestle with the savage heart of ASX-trading as per the free-ranging mind of Bell Direct’s market analyst Grady Wulff. [more…]
The Wulff: Debunking the Big Bank-tank narrative
The Wulff is Stockhead’s regular wrestle with the savage heart of ASX-trading as per the free-ranging mind of Bell Direct’s market analyst Grady Wulff. [more…]
Why ASX water tech stock SciDev is on the front line in fight against ‘forever chemicals’ PFAS
SciDev is an Australian leader in PFAS remediation The company is on a strong trajectory as PFAS makes headlines Stockhead reached out to SciDev’s CEO, [more…]
Why ASX water tech stock SciDev is on the front line in fight against ‘forever chemicals’ PFAS
SciDev is an Australian leader in PFAS remediation The company is on a strong trajectory as PFAS makes headlines Stockhead reached out to SciDev’s CEO, [more…]
Private lender Finexia sees ‘huge opportunity’ in ‘childcare generation’
Finexia Financial Group aims to become leading private lender to childcare sector in Australia The company works with operators to open up new centres as [more…]
Private lender Finexia sees ‘huge opportunity’ in ‘childcare generation’
Finexia Financial Group aims to become leading private lender to childcare sector in Australia The company works with operators to open up new centres as [more…]
Rise and Shine: Everything you need to know before the ASX opens
Good morning everyone, and welcome to 07 May, 2024 – an important date in the history of being bored to death by tales of someone else’s [more…]
Rise and Shine: Everything you need to know before the ASX opens
Good morning everyone, and welcome to 07 May, 2024 – an important date in the history of being bored to death by tales of someone else’s [more…]
Neurotech reports more positive Phase 1/2 Rett Syndrome clinical trial results
Further primary and secondary endpoint analysis of Neurotech’s Phase 1/2 trial has highlighted additional benefits NTI164 is the first broad-spectrum cannabinoid drug therapy to show [more…]
Neurotech reports more positive Phase 1/2 Rett Syndrome clinical trial results
Further primary and secondary endpoint analysis of Neurotech’s Phase 1/2 trial has highlighted additional benefits NTI164 is the first broad-spectrum cannabinoid drug therapy to show [more…]
